Critical Reviews in Oncology / Hematology Impact of hyperglycemia on the efficacy of chemotherapy—A systematic review of preclinical studies  Maaike C. Gerards, Daphne L. van der Velden, Joke W. Baars, Dees P.M. Brandjes, Joost B.L. Hoekstra, Titia M. Vriesendorp, Victor E.A. Gerdes  Critical Reviews in Oncology / Hematology  Volume 113, Pages 235-241 (May 2017) DOI: 10.1016/j.critrevonc.2017.03.007 Copyright © 2017 The Author(s) Terms and Conditions

Fig. 1 Simplified pathways of the mechanisms described in the included studies. T-lines depict an inhibitory effect and arrows depict a stimulatory effect. Abbreviations: ER=Estrogen receptor. FAS=Fatty acid synthase. GLUT-1=glucose uptake transporter 1. IGF-BP2=Insulin growth factor binding protein-2. IGF-1(R)=insulin growth factor 1(-receptor). IR=insulin receptor. MDR-1=multidrug resistance protein-1. PGC-1a=Peroxisome proliferator-activated receptor y coactivator-1alpha. P53AIP1=p53-regulated apoptosis-inducing protein-1. PUMA=P53 Upregulated Modulator of Apoptosis. ROS=reactive oxygen species. TXN=Thioredoxin. TXN-IP=TXN interacting protein. Critical Reviews in Oncology / Hematology 2017 113, 235-241DOI: (10.1016/j.critrevonc.2017.03.007) Copyright © 2017 The Author(s) Terms and Conditions

Fig. 2 Risk of bias in preclinical studies. The bars indicate the percentage of studies that have either a low, high or unclear risk of bias. Random sequence generation, allocation concealment and random outcome assessment are classified as not applicable for cell culture studies. Critical Reviews in Oncology / Hematology 2017 113, 235-241DOI: (10.1016/j.critrevonc.2017.03.007) Copyright © 2017 The Author(s) Terms and Conditions